Form 4: Akero Therapeutics Senior VP Acquires Shares Through Employee Stock Purchase Plan

Sentiment:

Insider Transaction Report


Akero Therapeutics' Senior VP of Commercial Strategy, Patrick Lamy, acquired 193 shares of common stock at $23.868 per share through the company's Employee Stock Purchase Plan.

Summary

  • Patrick Lamy, Senior VP, Commercial Strategy at Akero Therapeutics, Inc. (AKRO), acquired 193 shares of common stock.
  • The transaction is reported to have occurred on June 30, 2025.
  • Shares were purchased at a price of $23.868 per share.
  • The acquisition was made under the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan (ESPP).
  • The purchase price represents 85% of the closing price of the Issuer's common stock on January 2, 2025.
  • Following this transaction, Patrick Lamy directly beneficially owns 31,891 shares of common stock.
  • The transaction is exempt under Rule 16b-3(c) and Rule 16b-3(d).

Sentiment

Score: 7

Explanation: The acquisition of shares by a Senior VP, even through an Employee Stock Purchase Plan, generally indicates management's confidence in the company's future prospects and aligns their interests with shareholders. The discounted purchase price is a standard feature of ESPPs.

Positives

  • Management (Senior VP) is increasing their direct ownership in the company, which can signal confidence in future performance and aligns their interests with shareholders.
  • The acquisition was made through an Employee Stock Purchase Plan (ESPP), indicating participation in a broad-based employee benefit program.
  • The shares were acquired at a discounted price of 85% of the closing price on January 2, 2025, a standard benefit of ESPPs.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

  • Shareholders: Potentially positive signal due to insider buying, aligning management interests with shareholder value.
  • Employees: Demonstrates the availability and utilization of employee benefit plans like the Employee Stock Purchase Plan.

Key Dates

DateDescription
01/02/2025Closing price used as a basis for the 85% discount calculation for the ESPP share purchase.
06/30/2025Date of the reported transaction where 193 shares were acquired.
07/02/2025Date the Form 4 filing was signed by the Attorney-in-Fact.

Recommendation

hold

Keywords

Akero Therapeutics, AKRO, Form 4, Insider Transaction, Stock Purchase, Employee Stock Purchase Plan, ESPP, Patrick Lamy, Common Stock, Share Acquisition

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.